Audio Interview with David Schrader, Chief Operating Officer at Scythian Biosciences (TSX.V: $SCYB.V)
August 15, 2017 (Investorideas.com Newswire) Investorideas.com, a global news source and investor resource covering cannabis and biotech stocks issues an exclusive podcast interview with David Schrader, Chief Operating Officer at Scythian Biosciences Corp. (TSXV: SCYB).
Scythian Biosciences Corp. seeks to develop the first accepted drug regimen for concussion and traumatic brain injury with their cannabinoid-based combination drug therapy.
"There is no currently accepted drug regimen for the treatment of traumatic brain injury and concussion," said Scythian's Chief Operating Officer, David Schrader.
Schrader explained that after sustaining an injury to the head, further damage is often caused by the body's natural responses.
"Aside from the initial impact, there's a couple of processes that happen in the brain that cause continuing brain injury even after the initial injury occurs," he said. "The process of inflammation, and the body's own immune response, which releases things such as cytokines, which are different chemicals in the immune process and they trigger other immune processes."
Schrader said that the company's research had led them to the use of cannabinoids.
"We started researching into the manner in which concussion causes injury to the brain, and we noted a link that there are several cannabinoids that actually work to stop up the symptoms and the processes that are causing this brain tissue injury," he said. "From our research we learned that there are several brain receptors that are involved in this process and that cannabinoids actually work and trigger these different brain receptors."
"We have come up with a combination of two different drugs, which we've compiled together into a single drug that we're hoping will be available orally," he said. "One of them works on the CB2 receptor, which is what CBD works on, and CBD is a chemical that's very heavily in marijuana but it's not psychoactive."
"We've added a second drug into the mix, which works on the NMDA receptor," he said. "Each of these two receptors basically helped control and modulate this immune response. The hope is that through the use of administering these two different drugs after traumatic brain injury, it will minimize the amount of inflammation and immune response, and by doing that preventing a lot of the secondary brain damage."
Scythian is partnered with the University of Miami, where their research is done under Dr. Gillian A. Hotz, research professor at the university's Miller School of Medicine. Schrader said that if progress continues, they could be looking at clinical testing in the next couple of years.
"We have teamed up with a big group of doctors down there, that are headed up by Gillian Hotz, and they're doing our research for us," he said. "Right now they're in the process of doing pre-clinical testing. After that, assuming everything works out well, they'll be doing the clinical testing on humans, hopefully in the next two years."
Apart from their work to create a drug regimen for concussions and brain injury, Schrader said Scythian has a second project already in the works.
"We have a second patent application that's already pending for the treatment of gastro-intestinal inflammatory disease," he said. "That's the next project we're going to be working on."
Listen to the full podcast interview :
Audio Interview with David Schrader, COO at Scythian Biosciences (TSX.V: SCYB)
Scythian (http://scythianbio.com/) is a research and development company committed to finding a solution for the prevention and treatment of concussions and traumatic brain injury with its proprietary Cannabinoid combination.
Scythian's mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and clinical trials of its drug regimen. The University of Miami believes that Scythian's scientific approach shows significant promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian's clinical studies to be undertaken at their world-class facilities.
Gillian A. Hotz, PhD, is leading Scythian's program at the University of Miami. Dr. Hotz is a nationally recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of Medicine's Concussion Program since 1995.
Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.
About Investorideas.com - News that Inspires Big Ideas
The Investorideas.com podcasts are also available on iTunes, Tunein, Sticher. Spreaker.com, iHeart.com and Google Play Music.
Visit the Podcast page at Investorideas.com: http://www.investorideas.com/Audio/
Subscribe to Investorideas.com Podcast RSS:
Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Scythian Biosciences Corp. (SCYB) is a paid featured company on the 420 Cannabis Investor Ideas Directory and is a paid featured cannabis company and biotech for news, social media and PR effective August 7th for 2 months. More details - http://www.investorideas.com/About/News/Clientspecifics.asp
Visit Profile page: http://www.investorideas.com/CO/SCYB/